Pfizer Corporation

Mission Therapeutics Limited

Warner-lambert Company

Ziarco Pharma Ltd.

Other

Missions Therapeutics Limited

Gavin Alistair Whitlock

Martin Stockley

Mark Kemp

Alison Jones

Karl Richard Gibson

Paul Vincent Fish

Andrew Madin

Florian Michel Wakenhut

Christoph Martin Dehnhardt

Peter M Jones

Jotham Wadsworth Coe

Kevin Neil Dack

Kim James

Joseph Walter Strohbach

Alan Stobie

Paul Alan Glossop

Mark David Andrews

Michael David Woodrow

Yogesh Anil Sabnis

Yogesh Sabnis

Usa Datta

Jackie Diane Kendall

Alan Daniel Brown

Michael J Fray

Simon Bailey

Julian Blagg

Thomas Ryckmans

Mark Ian Lansdell

Nicholas Murray Thomson

Michael Jonathan Fray

Mark Llewellyn Lewis

Steven Wade Korturn

Steven Wade Kortum

Paul Brennan

Keith Allan Menear

R Ian Storer

Malcolm Christian Mackenny

Mark Ian Kemp

Martin Lee Stockley

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

Compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein. 

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, Z, Y and m are as defined herein. 

1-cyano-pyrrolidine compounds as USP30 inhibitors

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable sat thereof, wherein R, R, R, R, R, R, R, R, R, Z, Y and m are as defined herein. 

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, Z, Y and m are as defined herein. 

The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer. 

2-cyanoisoindoline derivatives for treating cancer

The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer. 

The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.

Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors

A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A' are C or N, where C may be substituted by halo or C-Calkyl; R and Rare selected from the group consisting of H, C-Calkyl, &#x2014;(CH)&#x2014;W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, &#x2014;NR&#x2033;SO&#x2014;R&#x2032;, etc., where R&#x2032; and R&#x2033; are C-Calkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and Ro and the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; Ris H, halo or cyano; Rand Rare H, C-Calkyl, etc.; X is a bond, etc.; Ris H, C-Calkyl, etc.; Y is a bond, &#x2014;(CH)&#x2014;, etc. The invention also relates to compositions and uses in the treatment of various diseases.

Pyrazolopyridines and pyrazolopyrimidines

Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors

Growing community of inventors

Deal, United Kingdom

Gavin Alistair Whitlock